In an adult male receiving testosterone injection for hypogonadism, should the testosterone be discontinued before undergoing total knee replacement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Testosterone Should Be Held Before Total Knee Replacement

Based on recent high-quality evidence, testosterone injections should be discontinued in the perioperative period before total knee replacement due to significantly increased risks of reoperation and infection.

Key Evidence Supporting Discontinuation

The most recent and highest quality study 1 demonstrates that male patients prescribed testosterone replacement therapy (TRT) within one year prior to primary TKA face substantially elevated risks:

  • Significantly higher cumulative incidence of reoperation for infection at 1,2,3,4, and 5 years postoperatively (all p<0.05)
  • Significantly higher all-cause reoperation rates at all time points through 5 years
  • This held true even after matching for demographics, comorbidities (diabetes, hypertension, obesity, smoking), and other confounding factors

Additional supporting evidence 2 shows that intramuscular testosterone formulations carry particularly high risk, with 18.5% revision rate in IM users versus 3% in topical users (p=0.046). Of the six revisions identified, five occurred in the IM testosterone group.

Clinical Reasoning

Why Testosterone Increases Surgical Risk

While the Endocrine Society guidelines 3, 4 provide comprehensive monitoring protocols for testosterone therapy, they do not address perioperative surgical risk. The guidelines focus on:

  • Hematocrit monitoring (stop if >54%)
  • PSA surveillance
  • Cardiovascular monitoring

However, these monitoring parameters don't capture the infection and reoperation risks specific to orthopedic surgery.

Mechanism of Increased Risk

The elevated infection risk likely relates to:

  • Immunomodulatory effects of supraphysiological testosterone levels
  • Increased hematocrit (testosterone raises hemoglobin dose-dependently 3, 4), potentially affecting tissue perfusion
  • Higher serum testosterone levels with IM formulations (652.6 ng/dL vs 356.1 ng/dL for topical 2)

Practical Recommendations

Timing of Discontinuation

  • Hold testosterone at least 4-6 weeks before surgery to allow:
    • Normalization of hematocrit (testosterone enanthate/cypionate half-life is approximately 8 days)
    • Reduction of immunomodulatory effects
    • Clearance of supraphysiological levels

Formulation-Specific Considerations

  • IM testosterone (enanthate/cypionate): Requires longer washout due to depot effect
  • Topical formulations: Shorter washout period acceptable (steady-state achieved within 1 week 4)
  • Testosterone pellets: May require 3-6 months for complete clearance

Monitoring Before Surgery

Check baseline hematocrit before proceeding with surgery:

  • If hematocrit >50%, delay surgery until <50% 3, 4
  • This is already a relative contraindication to testosterone therapy per guidelines

When to Resume

  • Wait until wound healing is complete (typically 6-12 weeks post-TKA)
  • Confirm no signs of infection before restarting
  • Consider switching from IM to topical formulation to reduce future surgical risk 2

Important Caveats

Balancing Hypogonadism Symptoms

While one older study 5 suggested preoperative supraphysiological testosterone might improve functional recovery, this was:

  • A small pilot study (n=25)
  • Published in 2002, before current infection risk data
  • Contradicted by multiple recent large-scale studies showing increased complications 1, 2, 6

The mortality, morbidity, and quality of life risks from infection and reoperation far outweigh any theoretical functional benefits.

Patient Counseling

Inform patients that:

  • Temporary discontinuation is for surgical safety
  • Hypogonadism symptoms may temporarily worsen but are manageable
  • Therapy can be resumed after successful healing
  • The alternative is 2-5x higher risk of reoperation requiring additional surgery, antibiotics, and prolonged recovery

Documentation

Document in the medical record:

  • Discussion of testosterone discontinuation
  • Patient agreement to hold therapy
  • Plan for resumption post-recovery
  • Baseline testosterone and hematocrit levels

Contraindications to Holding (Rare)

The only scenario where continuing might be considered is severe symptomatic hypogonadism where discontinuation poses immediate health risks. However, elective TKA should be postponed in such cases until the patient is medically optimized, rather than proceeding with active testosterone therapy.

The evidence is clear: testosterone increases surgical complications in TKA, and temporary discontinuation is the prudent approach to minimize preventable morbidity 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.